NPM1 and acute myeloid leukemia: Other PCR strategies targeting intermediate-risk patients with nucleophosmin (NPM1) insertion mutations, who comprise about 30% of all AML cases [10] and half of patients with normal cytogenetic profiles, first require identification of the insertion type and subsequent use of mutation-specific PCR primers for longitudinal tracking over time [20].